Several studies using in vivo models of PD demonstrated beneficial effects of IGF1 treatment by preventing dopaminergic neuronal loss in the SN (Ebert et al., 2008), improving motor performance in a rat model of PD (Guan et al., 2000; Krishnamurthi et al., 2004). Here, IGF1 is linked to Parkinson disease.